Overview

Efficacy of Erlotinib in Neoadjuvant Setting in Patients With Stage IIIA, N2-positive Non-Small Cell Lung Cancer

Status:
Completed
Trial end date:
2012-12-01
Target enrollment:
Participant gender:
Summary
This study propose neoadjuvant chemotherapeutic role by erlotinib.
Phase:
Phase 2
Details
Lead Sponsor:
Samsung Medical Center
Treatments:
Erlotinib Hydrochloride